• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Durso Jerome Benedict

    2/25/25 5:44:25 PM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALT alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Durso Jerome Benedict

    (Last) (First) (Middle)
    C/O ALTIMMUNE, INC.
    910 CLOPPER ROAD, SUITE 201S

    (Street)
    GAITHERSBURG MD 20878

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    02/24/2025
    3. Issuer Name and Ticker or Trading Symbol
    Altimmune, Inc. [ ALT ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    Remarks:
    Exhibit 24 - Power of Attorney
    No securities are beneficially owned.
    /s/ Gregory Weaver, as Attorney-in-Fact 02/25/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $ALT alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ALT

    DatePrice TargetRatingAnalyst
    2/28/2025Mkt Perform
    William Blair
    1/8/2025$18.00Buy
    Stifel
    11/12/2024$26.00Buy
    UBS
    4/29/2024Buy → Neutral
    Guggenheim
    1/24/2024$13.00Neutral
    Goldman
    3/22/2023$20.00 → $6.00Buy → Neutral
    Goldman
    12/1/2022$20.00Buy
    Goldman
    12/29/2021$30.00Buy
    Jefferies
    More analyst ratings

    $ALT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Sohn Catherine A. bought $5,784 worth of shares (1,000 units at $5.78) (SEC Form 4)

      4 - Altimmune, Inc. (0001326190) (Issuer)

      3/18/25 4:15:22 PM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Weaver Gregory L bought $51,996 worth of shares (10,000 units at $5.20) (SEC Form 4)

      4 - Altimmune, Inc. (0001326190) (Issuer)

      3/14/25 7:27:34 AM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Medical Officer Harris Matthew Scott gifted 67,787 shares (SEC Form 4)

      4 - Altimmune, Inc. (0001326190) (Issuer)

      3/11/25 4:05:11 PM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • William Blair initiated coverage on Altimmune

      William Blair initiated coverage of Altimmune with a rating of Mkt Perform

      2/28/25 7:17:56 AM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stifel initiated coverage on Altimmune with a new price target

      Stifel initiated coverage of Altimmune with a rating of Buy and set a new price target of $18.00

      1/8/25 7:32:53 AM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UBS initiated coverage on Altimmune with a new price target

      UBS initiated coverage of Altimmune with a rating of Buy and set a new price target of $26.00

      11/12/24 7:30:53 AM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALT
    SEC Filings

    See more
    • Altimmune Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - Altimmune, Inc. (0001326190) (Filer)

      6/26/25 7:30:26 AM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Altimmune Inc.

      SCHEDULE 13G/A - Altimmune, Inc. (0001326190) (Subject)

      5/15/25 11:05:50 AM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Altimmune Inc.

      10-Q - Altimmune, Inc. (0001326190) (Filer)

      5/13/25 4:55:02 PM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Altimmune Announces Positive Topline Results from the IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH

      First product candidate to demonstrate significant MASH effects and weight loss at 24 weeks Trial met its primary endpoint with statistically significant MASH resolution without worsening of fibrosis in up to 59.1% of participants in an ITT analysis Fibrosis improvement without worsening of MASH in up to 34.5% of participants in an ITT analysis Supplemental AI-based analysis demonstrated statistically significant reductions in liver fibrosis at 24 weeks Weight loss of up to 6.2% at 24 weeks with no plateauing Potentially best-in-class tolerability, with less than 1% treatment discontinuations due to adverse events in pemvidutide-treated participants Conference call to be held on June 2

      6/26/25 7:00:00 AM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Altimmune to Announce Topline 24 Week Results from its IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH on Thursday, June 26

      GAITHERSBURG, Md., June 25, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, will host an investor webcast on Thursday, June 26, 2025 at 8:30 am E.T. to present topline 24 week data from its IMPACT Phase 2b trial evaluating pemvidutide in the treatment of patients with metabolic dysfunction-associated steatohepatitis (MASH). Conference Call InformationThe Company will host a conference call and webcast at 8:30 am E.T. on June 26, 2025. The call will include remarks from Altimmune management and Dr. Mazen Noureddin, Professor of Medicine at the H

      6/25/25 7:12:07 PM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Altimmune Announces Multiple Presentations at Upcoming American Diabetes Association's Scientific Sessions

      GAITHERSBURG, Md., June 13, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced an oral presentation and three poster presentations on pemvidutide at the American Diabetes Association's (ADA) 85th Scientific Sessions, to be held in Chicago, IL from June 20-23, 2025. Pemvidutide is a novel, investigational GLP-1/glucagon dual receptor agonist under development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), obesity, alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). Details for the oral prese

      6/13/25 7:30:00 AM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Sohn Catherine A. bought $5,784 worth of shares (1,000 units at $5.78) (SEC Form 4)

      4 - Altimmune, Inc. (0001326190) (Issuer)

      3/18/25 4:15:22 PM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Weaver Gregory L bought $51,996 worth of shares (10,000 units at $5.20) (SEC Form 4)

      4 - Altimmune, Inc. (0001326190) (Issuer)

      3/14/25 7:27:34 AM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALT
    Leadership Updates

    Live Leadership Updates

    See more
    • Seasoned Biopharmaceutical Industry Executives Teri Lawver and Jerry Durso Appointed to Altimmune Board of Directors

      Ms. Lawver, former Chief Commercial Officer of Dexcom and Global Vice President at Johnson & Johnson responsible for billion-dollar Immunology and Cardiovascular & Metabolism Portfolios over her 20-year career Mr. Durso led biopharmaceutical company focused on liver disease as former CEO of Intercept Pharmaceuticals, previously oversaw multiple blockbuster franchises including cardiovascular and diabetes during 22-year tenure at Sanofi GAITHERSBURG, Md., Feb. 25, 2025 (GLOBE NEWSWIRE) --  Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced the expansion of its Board of Directors with the appointments of Teri Lawver and Jerry Durso. "We are thrilled

      2/25/25 7:30:00 AM ET
      $ALT
      $DXCM
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments
    • Altimmune Appoints Former GSK Executive Catherine Angell Sohn, Pharm.D. to its Board of Directors

      GAITHERSBURG, Md., March 27, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced the appointment of Catherine Angell Sohn, Pharm.D. to its Board of Directors. "We are delighted to welcome Catherine to our Board of Directors," said Vipin K. Garg, Ph.D., President and Chief Executive Officer. "Her broad experience in the pharmaceutical industry including strategic product development, business development and commercialization will be invaluable to Altimmune as we pursue our mission to develop next generation peptide therapeutics for obesity and liver disease." Dr. Sohn added, "I am very honored and pleased to join the Altimmun

      3/27/23 4:05:00 PM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Altimmune Appoints Raymond Jordt as Chief Business Officer

      GAITHERSBURG, Md., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced the appointment of Raymond Jordt as Chief Business Officer, effective January 1, 2023. Mr. Jordt succeeds José Ochoa, who is leaving Altimmune to pursue other opportunities. Mr. Jordt is an accomplished executive with over 25 years of experience in the pharmaceutical industry. He joins Altimmune from Eli Lilly and Company, where he spent nearly two decades in various corporate and business development roles, most recently as Head of Transactions. During his tenure at Lilly, he led acquisitions, in/out-licensing, divestitures, collaborations, option

      1/4/23 7:30:00 AM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Altimmune Inc.

      SC 13G/A - Altimmune, Inc. (0001326190) (Subject)

      11/14/24 11:58:56 AM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Altimmune Inc.

      SC 13G/A - Altimmune, Inc. (0001326190) (Subject)

      10/17/24 11:16:51 AM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Altimmune Inc.

      SC 13G/A - Altimmune, Inc. (0001326190) (Subject)

      10/16/24 4:21:16 PM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALT
    Financials

    Live finance-specific insights

    See more
    • Altimmune Announces Positive Topline Results from the IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH

      First product candidate to demonstrate significant MASH effects and weight loss at 24 weeks Trial met its primary endpoint with statistically significant MASH resolution without worsening of fibrosis in up to 59.1% of participants in an ITT analysis Fibrosis improvement without worsening of MASH in up to 34.5% of participants in an ITT analysis Supplemental AI-based analysis demonstrated statistically significant reductions in liver fibrosis at 24 weeks Weight loss of up to 6.2% at 24 weeks with no plateauing Potentially best-in-class tolerability, with less than 1% treatment discontinuations due to adverse events in pemvidutide-treated participants Conference call to be held on June 2

      6/26/25 7:00:00 AM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Altimmune to Announce Topline 24 Week Results from its IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH on Thursday, June 26

      GAITHERSBURG, Md., June 25, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, will host an investor webcast on Thursday, June 26, 2025 at 8:30 am E.T. to present topline 24 week data from its IMPACT Phase 2b trial evaluating pemvidutide in the treatment of patients with metabolic dysfunction-associated steatohepatitis (MASH). Conference Call InformationThe Company will host a conference call and webcast at 8:30 am E.T. on June 26, 2025. The call will include remarks from Altimmune management and Dr. Mazen Noureddin, Professor of Medicine at the H

      6/25/25 7:12:07 PM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Altimmune Announces First Quarter 2025 Financial Results and Business Update

      Top-line data from IMPACT Phase 2b trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH) expected in Q2 2025 Phase 2 trials in Alcohol Use Disorder (AUD) and Alcohol Liver Disease (ALD), expected to initiate in Q2 and Q3 2025, respectively Cash, cash equivalents and short-term investments of $150 million as of March 31, 2025 $100 million credit facility secured with Hercules Capital, adding balance sheet strength and financial flexibility to support continued development of pemvidutide Webcast to be held today, May 13, 2025, at 8:30 a.m. ET GAITHERSBURG, Md., May 13, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceuti

      5/13/25 7:00:00 AM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care